eftilagimod alfa clinical trials

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

This study is looking at a new treatment called efti, combined with standard care, for advanced lung cancer. It compares how well this combination works against the standard care alone to see if it helps people live longer and stops cancer from growing for longer. Participants will receive treatment for up to two years.